key: cord-0809830-nphdtsbt authors: Woodruff, M.; Ramonell, R.; Cashman, K.; Nguyen, D.; Ley, A.; Kyu, S.; Saini, A.; Haddad, N.; Chen, W.; Howell, J. C.; Ozturk, T.; Lee, S.; Estrada, J.; Morrison-Porter, A.; Derrico, A.; Anam, F.; Wu, H.; Le, S.; Jenks, S.; Hu, W.; Lee, F. E.-H.; Sanz, I. title: Critically ill SARS-CoV-2 patients display lupus-like hallmarks of extrafollicular B cell activation date: 2020-05-03 journal: medRxiv : the preprint server for health sciences DOI: 10.1101/2020.04.29.20083717 sha: dd2356de0eb734266de56312eff7524fa3b70868 doc_id: 809830 cord_uid: nphdtsbt Wide heterogeneity of disease course ranging from asymptomatic spread to respiratory failure and death has become a hallmark of the SARS-CoV-2 pandemic. While this clinical spectrum is well documented, its immunologic underpinnings are less clear. We have therefore, initiated studies of the B cell responses as they would participate in both early effector responses and in the initiation of memory formation. In terms of effector responses, we were particularly interested in the engagement and clinical correlates of the extra-follicular pathway (EF), we recently described in flaring SLE. In this systemic autoimmune disease, the EF pathway is initiated by newly activated naive B cell (aN) leading to large expansion of autoantibody-producing antibody-secreting cells through the generation of an epigenetically primed B cell precursor which are double negative (DN) for naive (IgD) and memory markers (CD27) and lacking expression of CXCR5 and CD21 (DN2). These highly activated D2 cells are also distinguished by high expression of CD11c and T-bet and are TLR7-driven. Both, TLR7-stimulation which is triggered by ssRNA and the central role played by their murine counterparts (typically characterized as Age-Associated B cells), in viral clearance, strongly supported the hypothesis that DN2 cells and the global EF pathway could be prominently engaged in COVID-19 patients. Also of note, EF B cell activation is particularly prominent in SLE patients of African-American ancestry, a population disproportionately represented in severe COVID-19. In this study we find that critically-ill patients with COVID-19 robustly upregulate constituents of the extrafollicular pathway, produce enormous numbers of antibody secreting cells, and lose unique transitional B cell populations that correlate with positive prognosis. This patient cluster associates tightly with biomarkers of poor outcomes and exhibits high rates of mortality. Thus, this B cell phenotype might serve as an immunological marker of severe COVID infection at early stages and could therefore identify a patient subset likely to benefit from targeted immunomodulatory therapy aimed at alleviating disease burden. As efforts intensify to identify treatment options and develop preventative vaccination strategies against COVID-19 infection 10, 11, 12, 13, 14, 15 , there is an urgent need for accurate characterization of protective (and nonprotective) humoral responses. With the recent description of a verified human extrafollicular B cell response, the continued identification of new human B cell subsets 16, 17, 18, 19 Table 1 ). To characterize humoral B cell response, we enrolled 17 patients with confirmed COVID-19 infection and 22 healthy adults (Supplemental Table 2 ). Of the COVID-19 group, nine were hospitalized and critically-ill requiring ICU admission with three of the 9 patients who eventually died. Peripheral blood was collected from these patients with a mean collection date of 12 days post-symptom onset to help ensure peak immune characterization. Despite early reports of lymphocytopenia 21 , initial characterizations of COVID-19 infection revealed an expanded CD19+ B cell fraction within the CD45+ hematopoietic compartment in comparison to healthy donors Table 3 ) to be used for multivariate patient clustering. Patients diagnosed with COVID-19 clustered independently from healthy controls, driven primarily by a population cluster containing ASCs and constituents of the extrafollicular (EF) response pathway such as active naive (aN) and double negative 2 (DN2) cells 17 (Fig 1c) . Direct assessment 4 EF pathway enrichment was notable with concomitant decrease of the transitional B cells, particularly a unique CD21 lo population making up as much as 10% of the total CD19+ B cells in the Tr-COV2 cluster (Fig 2a, 3a-d) . Surprisingly, while these cells shared several of the phenotypic markers of B cell immaturity such as high levels of CD10 and CD38 (Fig 3e) , they also expressed high levels of surface IgM with muted surface IgD (Fig 3f) , expression of the extrafollicular homing cues (Fig 3g) , and an increased expression of the plasma cell marker CD138 (Fig 3h) . In SLE, previous studies have identified the direct conversion of transitional B cell populations into ASCs in a polyclonal, autoreactive, and TLR-7 dependent manner 29 . Assessment of our SLE cohort revealed that while transitional populations were frequently decreased in comparison to healthy donors, CD21 lo transitional cell proportions were similar to COVID-19 + patients (Fig 3i) . Yellow Fever vaccinated patients show similar skewing, peaking at d12 post-vaccination (Fig 3j-k) . Alongside previous identification in HIV viremia 30 , these data suggest that this population may routinely emerge during ssRNA-antiviral responses. Due to their unique phenotype and association with mild disease, it will be important in future studies to fully characterize these cells and understand their impact on the clinical course of infection. To contextualize differences in clinical trajectory between the EF-CoV and Tr-CoV clusters, longitudinal data was collected from two patients within each cohort. All four were African American, and admitted to the ICU (Fig 4a) . While all of the patients displayed ASC expansion, the two from the EF-CoV cohort displayed consistently low levels of transitional B cells (Fig 4b-c ). These B cell subset parameters were associated with elevated Sequential Organ Failure Assessment (SOFA) scores (a marker of critical illness severity), and a corresponding decrease in PaO2 to FiO2 ratios -a prognostic measure of gas exchange efficiency while on mechanical ventilation (Fig 4d-e) . Additionally, these patients displayed elevated levels of C-reactive protein levels in the blood over their Tr-CoV counterparts (Fig 4f) . CRP, an acute phase reactant in the IL-6 pathway, has been increasingly used as a biomarker of COVID-19 severity 31, 32 . This trend in CRP values was generalizable, with blood CRP levels elevated across all critically ill SARS-CoV-2 patients, but particularly those within the IL-6-high EF-CoV cohort (Fig 4g) . Surprisingly, linear regression demonstrated that both the low frequency of transitional B cells and a high number of DN2 B cells across patients were correlated as strongly with CRP as IL-6 directly (Fig 4h-j) . Finally, as anticipated by their accumulation of poor prognostic 5 markers, patients within the EF-CoV group faced poor disease outcomes -EF-1 died on day 7 post-symptom onset and EF-2 was still critically ill as of day 24 post-symptom onset. More generally, this cohort suffered an exceptionally high disease burden with (5/6) experiencing kidney failure, 50% mortality and expected to rise. All patients in the Tr-CoV cluster were mild outpatients or have matriculated out of the ICU patient and near discharge. COVID-19 has vexed clinicians across the globe with its spectrum of illness severity and seemingly maladaptive immune response. Through careful humoral immunophenotyping, the current study offers four serious SARS-CoV-2 illness is highly associated with the same peripherally targeted and inflammatory extrafollicular response pathways found in serious autoimmune disorders; 3. decrease of transitional B cell pathways, whether correlative or causative, is an important indicator of poor disease outcome. Whether this observation reflects the loss of B cell regulatory function as postulated in SLE and other auto-inflammatory disorders, remains to be elucidated 36 ; and 4. due to disease heterogeneity, immunomodulatory therapy such as IL-6 inhibition may have discordant effects on different patient groups. Finally, it will be critical to determine if, as in SLE, pre-disposition towards extrafollicular B-cell activation may be compounding with socio-economic factors to result in the poor infection outcomes observed in the African American population. All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted May 3, 2020. Table 2 . To compare ASC responses between COVID-19 infection and vaccine responses, data was used from an additional healthy donors (n = 22) were recruited at Emory University who had not received a vaccination or experienced illness in the past 4 weeks prior to enrollment. Furthermore, 74 adults who received any of the following vaccines were recruited: quadrivalent influenza virus vaccine (n = 28), hepatitis A vaccine (n = 18), tetanus toxoid vaccine (n = 11), and live attenuated yellow fever virus vaccine (n = 17). Peripheral blood was collected in heparin sodium tubes (PBMCs) (BD Diagnostic Systems) at the peak of the ASC responses. Baseline subject demographics are included in Table 3 . All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted May 3, 2020. . Two subjects after receiving the yellow fever vaccine were enrolled in this study at Emory University in 2019. informed consent was given by all study subjects. PBMCs were isolated on the day the donor received the vaccine and on subsequent days after vaccination as reported in Fig 3. Peripheral blood samples were collected in heparin sodium tubes and processed within 6 hours of collection. PBMCs were isolated by density gradient centrifugation at 1000 x g for 10 minutes. Aliquots from the plasma layer were collected and stored at -80C until use. PBMCs were washed 2 times with RPMI at 500 x g for 5 minutes. Viability was assessed using trypan blue exclusion and live cells were counted using an automated hemocytometer. Cells were centrifuged again at 500 x g for 5 minutes, the supernatant was removed, and the cells were resuspended in one of two Ab cocktails (below). Cells were stained for 20 minutes at 4C in staining buffer, fixed for 10min in 0.4% PFA, and then washed for immediate flow cytometric immunophenotyping. Cells were analyzed on a Cytek Aurora flow cytometer using Cytek SpectroFlo software. Up to 3 x 106 cells were analyzed using FlowJo v10 (Treestar) software. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Dr. Lee is the founder of MicroB-plex, Inc and has research grants with Genentech. Dr. Hu has consulted for ViveBio LLC, AARP Inc, and Biogen Inc; has received research support from Fujirebio US; and has a patent on CSF-based diagnosis of FTLD-TDP. All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted May 3, 2020. . All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted May 3, 2020. . was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted May 3, 2020. . ANOVA analysis with Tukey's multiple comparison testing between groups. *p <= 0.05; **p <= 0.01; ***p <= 0.001; **** p <= 0.0001. All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted May 3, 2020. . was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted May 3, 2020. Plasma IL-6 (pg/mL) Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease Clinical characteristics of coronavirus disease 2019 in China Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Extrafollicular responses in humans and SLE Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus Epigenetic programming underpins B cell dysfunction in human SLE Age-Associated B Cells: A T-bet-Dependent Effector with Roles in Protective and Pathogenic Immunity Effective treatment of severe COVID-19 patients with tocilizumab Treatment of 5 critically ill patients with COVID-19 with convalescent plasma COVID-19: combining antiviral and anti-inflammatory treatments Spike protein binding prediction with neutralizing antibodies of SARS-CoV-2. bioRxiv COVID-19: A Review of Therapeutics Under Investigation